Two eye treatments face US FDA panel scrutiny in December
This article was originally published in Scrip
Executive Summary
The US FDAis convening its dermatologic and ophthalmic drugs advisory committee on December 5th to review two eye drugs. The panel will discuss Bausch & Lomb's NDA for besifloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.Allergan's NDA for bimatoprost ophthalmic solution 0.03% to stimulate eyelash growth (treatment of hypotrichosis of the eyelids) also will be reviewed. In the US Allergan sells bimatoprost under the Lumigan brand for reducing elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. The company anticipates global peak sales in the eyelash growth indication could exceed $500 million per year.